INTRODUCTION
Health development is directed to increase awareness, willingness, and ability of healthy life for everyone to improve the health of as high as can be realized. The impact of the success of health development characterized by rising life expectancy, lowered mortality rate and the birth mother [1]. According to the Central Bureau of Statistics Indonesia in 2013, life expectancy in Indonesia is 73 years for women and men is 69 years. National Development Planning Agency projected life expectancy in Indonesia in 2025 may reach 73.6 years [2].

In the United States, the elderly population aged over 65 years to reach 13% of the total population, but total consumption of drugs accounted for 33% of all prescriptions. In 2040, 25% of Americans are expected to consume the drug reaches 50% of all prescriptions. While in Singapore, in 2030 the elderly population is projected to 18.4% of the total population in Singapore [3].

The pattern of prescribing for someone with multiple diseases must be based on the best available evidence. The use of polypharmacy will give some impact on the elderly, including an increase in inappropriate treatment, adverse drug events (ADRs), and some of the problems that are affected by changes in pharmacokinetics and pharmacodynamics of drugs. Aging in the elderly with some illnesses, may potentially lead to use of many medicines, leading to inappropriate prescribing patterns, and contributing to adverse drug reactions and hospitalization. This review will describe the effect of polypharmacy in elderly patients.

Keywords: Polypharmacy, Adverse drug reactions, Drug-drug interactions, Elderly, Inappropriate medication.

POPULATION OF ELDERLY
United States defines the elderly as individuals who have 65-74 years of age, who have health problems and diseases, dependence on others as well as the problems the function and dysfunction of organs, while a very old age is an individual over the age of 85 years (the "oldest old" >85 years). According to statistical data, the geriatric population and the elderly will continue to increase, this increase will continue with a significant amount. The population in 2004 was 36.2 million and increase to 46.2 million in 2014, reaching up to 28%. When projected in the year 2060 will reach 98.2 million. Meanwhile, people who are older than 85 years has reached 6.2 million in 2014, will increase continuously and is projected to be 14.6 million in 2040 [7]. In Germany, the elderly population and which has very old has matched 4.5 million people, and 5.4% were aged 80 years or more. This population will continue to grow in the past decade. In Italy, they were very elderly (>85 years of age) is growing rapidly. Increased life expectancy and improving health in the elderly is an indicator of a country’s success in prevention of various diseases associated with the aging process [8]. The elderly aged 60 years and older is increasing rapidly. In 2010, the world’s population aged 60 and over was 11% and in 2030, will reach up to 16%. In the year 2025, Europe has been estimated that the percentage of the population aged 60 will reach up to 29%. They have special problems due to aging, changes in physiological functions, some diseases of the elderly, which can cause various health problems. As a result, the elderly will consume more drugs or polypharmacy, which can lead to serious risks and complications [9].

The increasing of health and welfare of the population will have an effect on the increase in life expectancy in Indonesia. According to the Indonesian Central Bureau of Statistics, it is estimated that in 2035 there are five provinces with the percentage of the population 65 years and over were highest at 14.9%, Central Java, East Java, 14.1%, 14.0% Yogyakarta, Bali 12.1%, and North Sulawesi 12.0%. Thus, the number of people 65 years and over in the province has reached more than 10% (of the total estimated population of Indonesia in 2035 amounted to 305 million people). The older population in 2035 is predicted to reach 15.77% [2].

CHANGE OF AGING
Aging is a multidimensional process. Normal aging and diseases associated with aging is an integral condition. Typically, the aging
process will lower physiological functions, for example; decreased bone density, osteoarthritis, and suffering cataract lens, while the diseases associated with old age, but does not occur in all people (aging probabilistic) is dementia, hypothyroidism, stroke, and congestive heart failure (CHF). Various studies of modern molecular and cellular biology have demonstrated the mechanism of aging, such as DNA damage, oxidative materials, free radical, catastrophic error; the aging process, apoptosis, immune, neuroendocrine, and others. Decrease integrative cell with a specific function (pituitary, thyroid, adrenal, pancreas, and glands gonads) cause abnormalities of homeostasis. Decreased organ function in the elderly is more prone to various diseases so that the elderly will receive many medications (polypharmacy) [10,11].

Androgens and anabolic growth hormones are hormones that contribute to the formation of muscle mass and strength, as we age, these hormones also decrease, so that people will lose strength, muscle mass, and muscle weakness [12]. Aging, clinically can be attributed to weakness in the muscles, fractures occur more easily, and a decrease in body mass index results in falls, trauma, infection, the risk of delirium, unstable blood pressure, and deterioration of other physical conditions [13]. Table 1 is an example of a physical examination of the elderly.

Being elderly is a lifelong process that cannot be avoided. It is a process of change of the physical, mental, and social. The success of health development and life cycle approach that starts from a mother preparing her pregnancy until the baby is born, toddlers, school-age children and adolescents, adults, and pre-elderly, will determine the quantity and the quality of life and health of the elderly in the future. If the health services at all stages of the life cycle are done well, it can be ascertained that the quality of life in the elderly will be good [14]. Individual treatment plans should be done by considering each drug pharmacokinetics and pharmacodynamics profile in certain patients because the drug can have different reactions in different patients, a specific profile should be developed for each patient. Aspects of this profile may include the following [16]:

- The medicine will give the pharmacokinetics and pharmacodynamics profile in certain patients
- The potential DIs in certain patients
- The potential for adverse drug reactions (ADRs) in certain patients
- The issue of patient adherence to pharmacotherapy plan.

**MULTI DISEASES**

Pathophysiology of the elderly should be assessed in an integrated manner by a health professional collaboration. A series of the disease, before and during treatment, family and social history, and demographic data need to be examined to assess the health of the elderly through geriatric assessment. Approach to medical records and physical examination in any very specific geriatric patient, including nutrition problems, sight, hearing, urine containment, balance and fall prevention, osteoporosis, and polypharmacy should be a concern in the treatment of the elderly [17]. The severity of the disease that accompanies the aging process in the elderly should be a concern for health professionals in assessing their condition. Table 2 provides an overview of the relationship between symptoms, diseases, and organ disorders.

**THE IMPACT CAUSED BY POLYPHARMACY**

In general, elderly people suffer from some chronic diseases, consequently using a drug that is more complex than other groups of age [20]. This group has a condition more severe disease than younger adults; due to changes in pharmacokinetics and pharmacodynamics in the elderly may affect the metabolism of drugs and drug side effects. Often the drugs used in the elderly are often inaccurate, which would be associated with health problems, including the incidence of drug side effects, and ADRs. Drugs given to the elderly need to be assessed on all aspects of elderly patients, taking account of comorbidity, complex treatment regimens, functional and cognitive status, the goals of therapy, and quality of life. A comprehensive evaluation is needed to improve the compliance of drug use in elderly patients were included, prescribing the wrong drug without indication, an indication without drugs [21].

- Wrong prescription is related to the prescription indication that led to a significantly increased risk of reaction/event associated with a drug that is not needed, such as incorrect medication dosage, treatment duration and method of use, as well as the clinical effects, including interactions with medicines drug or drug-disease
- Drugs without indication associated with prescription drugs that are not in accordance with the patient’s clinical condition or medications used for clinical treatment, but they are used to prevent or prophylaxis against certain other diseases
- Indication without prescription relating to drugs clinical need, not given. The impact of polypharmacy in elderly patients as shown in Fig. 1.

**Association between polypharmacy and ADEs/ADRs**

Multimorbidity and polypharmacy generally will increase the risk of ADR. ADR will be difficult to avoid having to consider the treatment of patients with possible inappropriate prescribing and potential risk in the elderly. Another reason, pharmacokinetic properties may change in elderly patients so that the dose needs to be adjusted to avoid the incidence of drug side effects [22]. The prevalence of polypharmacy, inappropriate prescriptions, and ADR interlinked, therefore, should be assessed to adjust the drug is needed, so that a given drug needs to pay attention to patient safety in elderly patients [23]. The incidence rate of polypharmacy, inappropriate prescriptions, and ADR are interrelated. The improvement in the quality of the prescription, the selection of the appropriate doses, avoids drug-DIs (DDIs), can reduce ADEs. An appropriate of prescribing is the key issue to improving drug safety in the elderly [24].

Frequent of inappropriate prescription can lead to the risk of falling in elderly patients. It is also associated with polypharmacy [25]. Besides, to avoid the side effects of medication, dosage, formulation, and administration need to be adjusted according to the age and condition of the patient, even some certain medication use should be avoided [26].

Polypharmacy in elderly patients in Singapore showed that the...
prevalence of the risk of drug-related problems (DRPs) is strongly influenced by the numbers of medication received by elderly patients, as well as these have the potential risk of occurrence of side effects of drugs, and even become one of the causes of the increase of the elderly treated in the emergency room in hospital [27]. In a retrospective study of the elderly population reported that use of the drug two or three types, the potential occurrence of DIs. Elderly patients who received treatment with five or more types of drugs have the potential risk of DIs is 4 times greater [28]. Polypharmacy was found to be a significant predictor of DIs-related ADR. The incidence of DIs-related ADRs in elderly outpatients was increased with the patient's age, number of diagnosed diseases, and number of drugs consumed [29].

Association between polypharmacy and DRPs

Calderón-Larrañaga et al. [30] suggest that the effect of age on ADEs might disappear when the variable level of multimorbidity is considered, and the occurrence of ADEs should also take into consideration of polypharmacy, include medications administered at a hospital or over-the-counter drugs [30]. The chronic health conditions and high medication consumption and inadequate drug therapy led to various DRPs. The hospitalization rate had a higher prevalence in patients admitted due to DRPs (12.1%) than patients admitted due to ADRs (7%) and ADEs (4.6%). The most DRPs were encountered among adult patients admitted with CVDs and diabetes. The main causes of hospitalization due to old age and polypharmacy were highly represented among patients admitted to hospitals due to DRPs [32].

A polypharmacy, non-compliance, and prescription errors were underlying reasons for developing DRPs. A few studies classified DRPs based on severity and preventability. Few studies classified DRPs based on severity and preventability. They reported that the cost for the management of DRP was directly proportional to severity. A hospital should bring down therapy cost incurred to treat DRP admissions to a greater extent (Table 3) [33].

Table 2: Review of system organ in elderly [18,19]

| System                  | Symptoms                                                                 | Possible problems                                      |
|-------------------------|--------------------------------------------------------------------------|--------------------------------------------------------|
| Visual                  | Loss of near vision (presbyopia), Loss of central vision, Loss of peripheral vision, glare from lights at night, Eye pain | Common with age macular degeneration glaucoma, stroke, cataracts, glaucoma, temporal arteritis |
| Auditory                | Loss of high-frequency range (presbycusis), Hearing loss                 | Acoustic neurona, cerumen, Paget’s disease, drug-induced ototoxicity common with age |
| Cardiovascular          | Difficulty eating or sleeping, over-fatigue, shortness of breath, orthopnea | CHF                                                   |
| Pulmonary               | Chronic cough, shortness of breath, Difficult breathing                  | Chronic obstructive pulmonary disease                  |
| Gastrointestinal        | Constipation, Fecal incontinence                                         | Chronic obstructive pulmonary disease hypothyroidism, dehydration, hypokalemia, colorectal cancer, inadequate fiber, inactivity, drugs focol impaction, rectal carcinoma |
| Genitourinary           | Urinary frequency, hesitancy, Urinary incontinence                       | BPH estrogen deficiency, detrusor instability          |
| Musculoskeletal         | Proximal muscle pain/weakness joint pain back pain                       | Polymyalgia rheumatic osteoarthritis, rheumatoid arthritis osteoarthritis, osteoporotic compression fracture, cancer |
| Neurologic/psychiatric  | Syncope, Transient loss of power, sensation or speech, Persistent aphasia or dysarthria disturbance of gait, insomnia, Loss of memory extremities | Parkinson’s disease, stroke circadian rhythm disturbance, drugs, sleep apnea, mood disorder Alzheimer’s disease, multi-infarct dementia, Osteoarthritis, radiculopathy, intermittent claudication, night cramps CHF, venous insufficiency |
| Extremities             | Leg and foot swelling, Leg pain                                          |                                                        |

BPH: Benign prostatic hyperplasia, CHF: Congestive heart failure

Table 3: Categories of DRPs [3]

| Problem                      | Description                                                                 |
|------------------------------|------------------------------------------------------------------------------|
| Drug use without indication  | The patient get a drug for treatment no needed for medically indication       |
| ADR                          | The patient has a medical problem that is the result of an ADR or adverse effect |
| DIs                          | The patient has a medical problem by the resulting of DDI or drug disease interaction |
| Overdose or sub-therapeutic dose | The patient receive too much or too little of the necessary drug from the clinical indicated |
| Duration of treatment        | The patient receive some drug treatment for longer period of time than clinically indicated |
| Untreated condition          | The patient has a medical problem that requires drug therapy but is not receiving a drug for that condition |
| Clinical contra indication   | Use of a drug which is contraindicated for the patient because of existing medical problems |
| Therapeutic duplication      | Use of multiple drugs with similar pharmacological effect when single drug is adequate |

Associated between polypharmacy and PIMs

Polypharmacy is the biggest problem that contributed to the incident PIMs, caused to hospitalization, ADEs, particularly among the elderly, because of changes in the body’s response and their multimorbidity. The greatest risk factor for the elderly is polypharmacy, which is associated with drug-related problems, such as adverse effects, poor adherence to drug use, DIs or drug disease interactions, and the high risk of the syndrome geriatric. Polypharmacy is also defined as at least one drug delivery a type of medicine there is no clinical indication [34]. Below is a describing of correlation polypharmacy in geriatric patients. The age of 65 years (elderly), often accompanied by multi-pathology of chronic diseases, such as hypertension, diabetes, osteoporosis, heart disease, and other degenerative diseases, as it
also issues of independence and dependence properties, function and dysfunction of organs. Aging is a multidimensional process. Normal aging and diseases associated with aging are two separate conditions. Associated with the normal aging processes that decrease in physiological functions in living organisms, for example, bone loss, osteoarthritis, and cataracts. Diseases associated with aging, but not caused by aging and do not occur in all people (including probabilistic aging) including dementia, hypothyroidism, stroke, and CHF [10]. Administration of drugs in elderly individuals should take into account the physiological changes due to aging patients where there would be changes in the pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (drug action against target) [6,35,36].

- Multi-dose is an alternative to ordinary prescription dispensing for people with regular medication use combined with difficulties in handling and administering their drugs [37]
- Multi-dose users may be more exposed to potentially inappropriate drug use than ordinary prescription users
- However, multi-dose users seem to have a lower probability of potentially serious DIs

Younger elderly with multi-dose drug dispensing may have the most problems with potentially inappropriate drug use (Table 4).

### CONCLUSION

Polypharmacy in elderly patients is often difficult to avoid because it is associated with a number of diseases suffered by the elderly. Therefore, inappropriate prescribing is an important concern of health workers to avoid unwanted drug effects.

Administration of drugs in the elderly should pay attention to the pharmacokinetics and pharmacodynamics of drugs especially the adjustment of drug dose to avoid drug side effects and DDIs. Elderly patients were given five or more medications, need to be closely monitored because they are four times higher risk of undesired effects due to DDIs. The role of pharmacists in assessing polypharmacy in elderly patients is very important. Collaboration between the medical profession needs to be done to evaluate the best treatment outcomes in elderly patients. Elderly patients with multiple diseases, it may get more types of drugs in polypharmacy, and potentially increase the inappropriate prescription drugs, and contributes to ADEs, ADRs, and duration of hospitalization.

---

**Table 4: The impact of polypharmacy and PIMs among elderly**

| Country, period            | Method of research; number of samples, number of drugs | Tools of PIM evaluation | Result                                                                                   | References |
|----------------------------|--------------------------------------------------------|--------------------------|-----------------------------------------------------------------------------------------|------------|
| January and December 2012, Italy | The retrospective observational of 1027 patients aged 65 years. The mean of comorbidities was 2.96±1.286, and prevalence of polypharmacy was 85% | The 2012 Beers criteria, STOPP criteria, IPET criteria | An aging can lead to an increasing of polypharmacy. The comorbidity affects the level of PIMs so that the increasing of PIMs number will occur the increasing hospitalization | [38]       |
| October-December 2005, Sweden | The cross-sectional design of 731,105 older people aged ≥75 years. The mean number of polypharmacy, 4.7±3.3 (women), 4.5±3.2 (men) | Sjoqvist system          | The multi-dose use can more exposed to potential IDU                                  | [37]       |
| May 2013 and June 2013, Japan | The cross-sectional design of 69 patients aged ≥65 years. The mean prevalence of polypharmacy was 6.4±3.4 | Beers’ criteria STOPP/START criteria, IPET | The prevalence of IP among elderly home care and the risk factors for IP were associated of polypharmacy and specific underlying medical conditions | [39]       |
| Singapore, 2004            | A randomly selected of 454 patients elderly age >65 years. The mean prevalence of polypharmacy was 6.4 | HCFA                     | The prevalence of polypharmacy use and PIMs are high in nursing homes, thus more medication used may lead to significant ADs and DIs       | [3]        |
| A period of 3 months, Austrian | A monocentric prospective cohort study from 543 patients. The mean number of drugs was 7.5±3.8, unnecessary drugs were 36.3%, drugs to avoid in 30.1%, duplication in 7.6%, wrong dosage in 23.4% and possible DDIs in 65.8%, ADEs were identified in 17.8% | Beers criteria | Polypharmacy, IP, and ADEs were highly prevalent in elderly. Risk factors for ADEs were female sex, poly-morbidity, renal dysfunction and inappropriate prescribing. To improve drug safety, appropriate prescribing might be more important than simply reducing the number of prescribed drugs | [24]       |
| July 2004 and June 2005, Israel | A retrospective observational of 1027 patients aged ≥65 years. The mean of chronic disease was 6.3±2.6, and prevalence of polypharmacy was 5.9±2.4 | MMSE                     | No relationship was found between IPDs on discharge and age, sex, functional status, cognitive level, number of chronic diseases, and cause of admission | [40]       |
| Ireland in 2007            | A retrospective national population study (n=338,801) using, PIPs 27.392 (8%) were prescribed two and 10.103 (3%) were prescribed three or more. PPIs at maximum therapeutic dosage for >8 weeks was prescribed PIMs (56.560, 17%) | STOPP criteria         | Polypharmacy was strongly associated with PIMs                                           | [41]       |
| 23 January and 13 February 2013, Japan | The cohort of 2053 elderly patients aged ≥65 years, the average was 48.4% of patients were defined as PIMs. The PIM-induced ADEs were 8% of patients | "Beers Criteria: The Japanese V.2003" | The PIM prevalence associated with home health care was relatively high | [42]       |

(Contd...)
The HRs calculation demonstrated that at least one PIM occurred more frequently in men compared to women (OR: 1.32; 95% CI: 1.23-1.41). This finding supports the need for targeted interventions to address polypharmacy in the elderly.

Table 4: (Continued)

| Country, period | Method of research; number of samples; number of drugs | Tools of PIM evaluation | Result | References |
|-----------------|--------------------------------------------------------|-------------------------|--------|------------|
| September 2011, December 2011, May 2012 and July 2012, Germany | A retrospectively of 200 patients of age ≥65 years. The 88% received at least one PIM at admission, and median number of PIMs received by the patients was 4, ranging from 0 (in 12% of patients) to 8 (in 1% of patients) | FORTA, PRISCUS STOPP | Polypharmacy was identified as a risk factor for PIM use, and so reducing the total number of prescribed drugs might be a starting point to reduce PIM use | [43] |
| In 2007, Germany | A pseudonymized data of 804,400 patient aged ≥65 years. The older people 25.0% who received at least one PIM. The mean number of drugs was 6.2 (SD: 4.8) for women and 5.6 (SD: 4.7) for men | PRISCUS list | A large number of the drugs were prescribed four or more times in 88.8% of all older people, which is an indicator of long-term treatment | [44] |
| In 2010, Germany | A retrospectively, for 647,073 patients aged ≥65 years. The incidence of hospitalization was 39.44% cases | PRISCUS list | PRISCU | PIMs are associated with higher rates of ADEs associated with hospitalization | [45] |
| January 2009-December 2010, Germany | The cohort 392,337 ambulatory patients aged ≥65 years. There were 126,535 hospitalizations during the observation period, and 47,470 of them occurred within 180 days post first dispensing | PRISCU list | The PIM calculation demonstrated a significant association between excess hospitalization | [46] |
| July to December 2012, Taiwan | 141 patients aged ≥65 years with Barthel scale scores ≤60 and a regular intake of medication for chronic diseases | STOPP and Beers 2012 criteria | The high frequency of PIM in disabled older patients with chronic diseases, particularly those prescribed ≥6 medications | [47] |
| South India, 2013-2014 | 120 patients aged ≥60 years, 39 patients (32.5%) received inappropriate medication | STOPP and Beers 2012 criteria | Polypharmacy and inappropriate prescription showed a significant proportion of geriatric patients PIMs prescriptions for the elderly population who come to the Gondar University Hospital often occur | [48] |
| Ethiopia, 2011-2013 | The retrospective study of 1,252 patients, aged ≥65 years 347 (27.7%) were received at least one potentially inappropriate medication | Beers criteria (2012) | Polypharmacy and adverse drug reactions in the elderly: Challenges for the internist of the third millennium. J Comorbidity 2011;1:28-44. | [49] |

REFERENCES

1. Minister of Health of the Republic of Indonesia. No. 79. On the Implementation in the Hospital Care of the Elderly; 2014. Available from: http://www.ishk.or.id/ue/PMIC%20Pol%2079%20ttg%20Penyelenggaraan%20Pelayanan%20Geriatri%202014%20%20KS.pdf.
2. Indonesian Central Statistics Agency. Indonesia Population Projection; 2010-2035. Available from: http://www.bapenas.go.id/files/5413/9148/4109/Proyeksi Penduduk_Indonesia_2010-2035.pdf.
3. Mamun K, Lien CT, Goh-Tan CY, Ang WS. Polypharmacy and inappropriate prescribing, ADE: Adverse drug events, ADR: Adverse drug reactions, DI: Drug interactions, HR: Hazard ratios, SD: Standard deviation
4. Elliott RA, Booth JC. Problems with medicine use in older Australians: A review of recent literature. J Pharm Pract Res 2014;44:255-71.
5. Fauziyah et al. Polypharmacy in the elderly: Challenges for the internist of the third millennium. J Comorbidity 2011;1:28-44.
6. Kindt FB, O'Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging 2011;6:857-66.
7. Morley JE. Hormones and the aging process. J Am Geriatr Soc 2003;51 7 Suppl: S33-7.
8. Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology: Summary from the American geriatrics society/national institute on aging research conference on frailty in older adults. J Am Geriatr Soc 2006;54(6):991-1008.
9. McLean AJ, Morley JE, Vellas B. Path’s Principles and Practice of Geriatric Medicine. 5th ed. Chichester: John Wiley & Sons, Ltd.; 2012.
10. Meslin AJ, Le Couteur DG. Polypharmacy and adverse drug reactions in the elderly: Challenges for the internist of the third millennium. J Comorbidity 2011;1:28-44.
11. Groot M, Agarwal M. Understanding medication errors in the elderly. N Z Med J 2013;126(1385):62-70.
12. O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: Criteria, detection and prevention. Drugs Aging 2012;29(6):437-52.
13. Davies EA, O’Mahony MS. Adverse drug reactions in special populations - The elderly. Br J Clin Pharmacol 2015;80(4):796-807.
Japanese elderly taking antihypertensives: A retrospective database study. Drug Healthc Patient Saf 2013;5:143-50.

24. Schuler J, Dückelmann C, Beinidl W, Prinz E, Michalski T, Pichler M. Polypharmacy and inappropriate prescribing in elderly internal medicine patients in Austria. Wien Klin Wochenschr 2006;120(23-24):733-41.

25. Hanlon JT, Arzt MB, Pieper CF, Lindblad CJ, Sloane RJ, Ruby CM, et al. Inappropriate medication use among frail elderly inpatients. Ann Pharmacother 2004;38(1):9-14.

26. Milton JC, Hill-Smith J, Jackson SH. Prescribing for older people. BMJ 2008;336(7644):606-9.

27. Jayarama N, Sleave SK, Prabhabak R. Adverse drug reactions in adults leading to emergency department visits. Int J Pharm Pharm Sci 2012;4 Suppl 4:462-6.

28. Teka F, Teklay G, Ayalew E, Teshome T. Potential drug - Drug interactions among elderly patients admitted to medical ward of Ayder Referral Hospital, Northern Ethiopia: A cross sectional study. BMC Res Notes 2016;9(1):431.

29. Obreli Neto PR, Nobili A, de Lyra DP Jr, Pilger D, Guidoni CM, de Oliveira Baldoni A, et al. Incidence and predictors of adverse drug reactions caused by drug-drug interactions in elderly outpatients: A prospective cohort study. J Pharm Pharm Sci 2012;15(2):332-43.

30. Calderón-Larrañaga A, Poblador-Plou B, González-Rubio F, Gimeno-Feliu LA, Abad-Díez JM, Prados-Torres A. Multimorbidity, polypharmacy, referrals, and adverse drug events: Are we doing things well? Br J Gen Pract 2012;62(605):e821-6.

31. de Lyra DP, Kheir N, Abriata JP, da Rocha CE, Dos Santos CB, Péia IR. Impact of pharmaceutical care interventions in the identification and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeirão Preto (SP), Brazil. Ther Clin Risk Manag 2007;3(6):989-98.

32. Al-Hamid A, Ghaleb M, Aljadhey H, A slanpour Z. A systematic review of potentially inappropriate drug use: A nationwide register-based study of over 700,000 elderly. Scand J Prim Health Care 2008;26(2):86-91.

33. Nivya K, Sri Sai Kiran V, Ragoo N, Jayaprakash B, Sonal Sekhar M. Polypharmacy and inappropriate prescribing in elderly internal medicine patients: A retrospective database study. Drug Healthc Patient Saf 2013;5:143-50.